Chylomicron formation pathway

The **chylomicron formation pathway** is a multistep biological process occurring primarily in enterocytes of the small intestine. It is responsible for the packaging of dietary triglycerides, cholesterol, and other lipids into chylomicrons, which are large, triglyceride-rich lipoproteins. The process begins after dietary triglycerides and cholesterol are digested to monoglycerides and fatty acids, absorbed into enterocytes mainly by passive diffusion, and re-esterified in the endoplasmic reticulum to form triglycerides. Apolipoprotein B-48 provides the structural backbone for chylomicrons; it acquires lipids with the help of microsomal triglyceride transfer protein (MTP). These nascent chylomicrons are then processed through the Golgi apparatus and secreted via exocytosis into the lymphatic circulation (chyle), entering systemic circulation through the subclavian vein, so bypassing hepatic first-pass metabolism. During circulation, chylomicrons interact with high-density lipoproteins (HDLs), acquiring additional apolipoproteins needed for recognition and triglyceride hydrolysis by lipoprotein lipase in tissues[1][2][3][4][5]. **Note:** "Chylomicron formation pathway" is not a single molecule, receptor, or protein, but rather a complex cellular/biochemical process involving multiple molecular players (e.g., apolipoprotein B-48, MTP, NPC1L1, etc.) and is *not* itself considered a conventional therapeutic target in the way receptors or enzymes are. The appropriate targets related to this pathway would be the molecules essential to the process, such as NPC1L1 (targeted by ezetimibe) or microsomal triglyceride transfer protein. Therefore, - **is_target:** false - **is_incorrect:** true Because this entry refers to an entire pathway, not a discrete, actionable molecular target.

Other names

Chylomicron assembly pathwayChylomicron biosynthesis

Inhibition of intestinal cholesterol absorption (e.g., Niemann-Pick C1-like 1 (NPC1L1) protein inhibitor)[3]